Submit Manuscript  

Article Details


Feasibility of mesenchymal stem cell therapy for COVID-19:A mini review

Author(s):

Jingwen Li, Xinyi Wang, Na Li , Ying Jiang, Heqing Huang*, Tao Wang, Zhicheng Lin and Nian Xiong*   Pages 1 - 5 ( 5 )

Abstract:


Patients infected with SARS-CoV-2 carry the coronavirus disease 2019 (COVID-19) which involves multiple systems and organs with acute respiratory distresssyndrome (ARDS)as the most common complication, largely due to cytokine storms or dysregulated immunity. As such, there are many severe patients with complications such as cytokine storm syndrome (CSS), who have a high fatality rate. Neither specific anti-SARS-CoV-2 drugs nor vaccines exist currently. Current treatment relies mainly on self-recovery through patients' immune function. Mesenchymal stem cells (MSCs) is a kind of multipotent tissue stem cells, which have powerful anti-inflammatory and immune regulatory functions, inhibiting the cy-tokine storms. In addition, MSCs have a strong ability to repair tissue damage and reduce the risk of severe complications such as acute lung injury and ARDS, and hopefully reduce the fatality rate in these patients. There are several clinical researches completed for treating COVID-19 with MSCs, all reporting restoration of T cells and clinical safety. Here we dis-cuss the clinical prospect and conclude the therapeutic effects and potential mechanism for MSCs in treating COVID-19.

Keywords:

mesenchymal stem cells, immune, regulate, repair, COVID-19, secretome

Affiliation:

Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, Wuhan Red Cross Hospital, Wuhan, Hubei, Emergency Department, Wuhan Red Cross Hospital, Wuhan, Hubei, Department of Pediatrics, People's Hospital of Dongxihu District, Wuhan, Hubei, Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, Laboratory of Psychiatric Neurogenomics, McLean Hospital, Harvard Medical School; Belmont, MA 02478, Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei



Read Full-Text article